Changes in bone mineral density after adjuvant aromatase inhibitors and fracture risk in breast cancer patients.
Berruti
Alfredo
A
Tucci
Marcello
M
Mosca
Alessandra
A
Vana
Federica
F
Ardine
Mara
M
Dogliotti
Luigi
L
Angeli
Alberto
A
Bertoldo
Francesco
F
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000469:Alkaline Phosphatase / Q000097:blood; D000970:Antineoplastic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects / Q000627:therapeutic use; D047072:Aromatase Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D015415:Biomarkers / Q000097:blood / Q000652:urine; D015519:Bone Density / Q000187:drug effects*; D001943:Breast Neoplasms / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D002170:Canada; D017024:Chemotherapy, Adjuvant; D024042:Collagen Type I / Q000097:blood / Q000652:urine; D020847:Estrogen Receptor Modulators / Q000008:administration & dosage; D005260:Female; D050723:Fractures, Bone / Q000209:etiology*; D006801:Humans; D000077289:Letrozole; D008875:Middle Aged; D009570:Nitriles / Q000627:therapeutic use*; D010455:Peptides / Q000097:blood / Q000652:urine; D013629:Tamoxifen / Q000008:administration & dosage*; D016896:Treatment Outcome; D014230:Triazoles / Q000627:therapeutic use*
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047072:Aromatase Inhibitors; D015415:Biomarkers; D024042:Collagen Type I; D020847:Estrogen Receptor Modulators; D009570:Nitriles; D010455:Peptides; D014230:Triazoles; C052929:collagen type I trimeric cross-linked peptide; D013629:Tamoxifen; D000077289:Letrozole; D000469:Alkaline Phosphatase